NCT04880109View on ClinicalTrials.gov

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
COVID-19
Interventions
DRUG

APX-115

Oral administration of APX-115 100 mg capsule once daily for 14 days

DRUG

Placebo

Oral administration of placebo capsule once daily for 14 days

Trial Locations (3)

21401

Anne Arundel Medical Center, Baltimore

33012

Alternative Research Associates, LLC, Hialeah

77070

Millennium Physicians Group, Houston

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Aptabio Therapeutics, Inc.

INDIV